Korley, 511 patient convalescent plasma early treatment RCT: 396% higher mortality [p=0.22], 10% lower hospitalization [p=0.59], and 6% lower progression [p=0.7] https://c19p.org/korley
copied to clipboard
Early Convalescent Plasma for High-Risk Outpatients with Covid-19
et al., NEJM, doi:10.1056/NEJMoa2103784
RCT 511 emergency department patients, 257 assigned to convalescent plasma, showing no significant difference in outcomes.
|
risk of death, 396.0% higher, RR 4.96, p = 0.22, treatment 5 of 250 (2.0%), control 1 of 248 (0.4%).
|
|
risk of hospitalization, 10.0% lower, RR 0.90, p = 0.59, treatment 51 of 257 (19.8%), control 56 of 254 (22.0%), NNT 45.
|
|
risk of progression, 6.0% lower, RR 0.94, p = 0.70, treatment 77 of 257 (30.0%), control 81 of 254 (31.9%), NNT 52.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Korley et al., 8/18/2021, Randomized Controlled Trial, USA, North America, peer-reviewed, 28 authors, average treatment delay 3.7 days.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.